Cingulate Inc
CING3.970USD
+0.110+2.85%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
23.73MMarket Cap
LossP/E TTM
More Details of Cingulate Inc Company
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Inc Info
Ticker SymbolCING
Company nameCingulate Inc
IPO dateOct 07, 2021
CEOCallahan (Jennifer L)
Number of employees13
Security typeOrdinary Share
Fiscal year-endOct 07
Address1901 W. 47Th Place
CityKANSAS CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code66205
Phone19139422300
Websitehttps://www.cingulate.com/
Ticker SymbolCING
IPO dateOct 07, 2021
CEOCallahan (Jennifer L)
Company Executives of Cingulate Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Werth Family Investment Associates LLC
1.45%
Kestra Advisory Services, LLC
1.39%
The Vanguard Group, Inc.
1.09%
Geode Capital Management, L.L.C.
0.63%
Quantum Private Wealth, LLC
0.36%
Other
95.08%
Shareholders
Shareholders
Proportion
Werth Family Investment Associates LLC
1.45%
Kestra Advisory Services, LLC
1.39%
The Vanguard Group, Inc.
1.09%
Geode Capital Management, L.L.C.
0.63%
Quantum Private Wealth, LLC
0.36%
Other
95.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.35%
Corporation
1.50%
Investment Advisor/Hedge Fund
0.75%
Research Firm
0.27%
Other
94.13%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
33
295.34K
5.70%
--
2025Q3
44
295.34K
6.89%
+113.00
2025Q2
41
295.23K
5.36%
+158.62K
2025Q1
38
136.60K
4.92%
-48.84K
2024Q4
38
91.23K
3.95%
+40.70K
2024Q3
38
50.54K
3.01%
-30.23K
2024Q2
36
80.24K
1.97%
+46.92K
2024Q1
36
33.32K
1.85%
+25.60K
2023Q4
33
318.00
10.05%
-5.36K
2023Q3
30
5.68K
6.07%
+3.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Werth Family Investment Associates LLC
97.99K
1.75%
--
--
Aug 01, 2025
The Vanguard Group, Inc.
35.38K
0.63%
+24.62K
+228.78%
Jun 30, 2025
Geode Capital Management, L.L.C.
32.16K
0.57%
+1.76K
+5.78%
Jun 30, 2025
Quantum Private Wealth, LLC
10.00K
0.18%
--
--
Jun 30, 2025
LPL Financial LLC
12.18K
0.22%
+12.18K
--
Jun 30, 2025
Virtu Americas LLC
13.35K
0.24%
+13.35K
--
Jun 30, 2025
BofA Global Research (US)
7.50K
0.13%
+5.54K
+283.09%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Date
Type
Ratio
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Cingulate Inc?
The top five shareholders of Cingulate Inc are:
Werth Family Investment Associates LLC holds 97.99K shares, accounting for 1.75% of the total shares.
The Vanguard Group, Inc. holds 35.38K shares, accounting for 0.63% of the total shares.
Geode Capital Management, L.L.C. holds 32.16K shares, accounting for 0.57% of the total shares.
Quantum Private Wealth, LLC holds 10.00K shares, accounting for 0.18% of the total shares.
LPL Financial LLC holds 12.18K shares, accounting for 0.22% of the total shares.
Werth Family Investment Associates LLC holds 97.99K shares, accounting for 1.75% of the total shares.
The Vanguard Group, Inc. holds 35.38K shares, accounting for 0.63% of the total shares.
Geode Capital Management, L.L.C. holds 32.16K shares, accounting for 0.57% of the total shares.
Quantum Private Wealth, LLC holds 10.00K shares, accounting for 0.18% of the total shares.
LPL Financial LLC holds 12.18K shares, accounting for 0.22% of the total shares.
What are the top three shareholder types of Cingulate Inc?
The top three shareholder types of Cingulate Inc are:
Werth Family Investment Associates LLC
Kestra Advisory Services, LLC
The Vanguard Group, Inc.
Werth Family Investment Associates LLC
Kestra Advisory Services, LLC
The Vanguard Group, Inc.
How many institutions hold shares of Cingulate Inc (CING)?
As of 2025Q4, 33 institutions hold shares of Cingulate Inc, with a combined market value of approximately 295.34K, accounting for 5.70% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.19%.
What is the biggest source of revenue for Cingulate Inc?
In --, the -- business generated the highest revenue for Cingulate Inc, amounting to -- and accounting for --% of total revenue.
